U.S. Cannabinoids Market Size, Share & Trends Analysis Report By Product (Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinol (CBN), Cannabidiolic Acid (CBDa)), And Segment Forecasts, 2020 - 2027

Published: Dec, 2020 | Pages: 69 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

"U.S. Cannabinoids Market Growth & Trends

The U.S. cannabinoids market size is expected to reach USD 16.4 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 20.4% from 2020 to 2027. Growing consumer awareness regarding various health benefits offered by cannabinoids and growing number of new entrants in the market, leading to expansion in product availability are driving the market. Rising adoption and acceptance of cannabinoids based treatment among consumers over antibiotics treatment is likely to fuel the growth of the market. Furthermore, changing buyer perception and attitude toward these products is further bolstering revenue growth.

Based on product, the cannabidiol (CBD) segment dominated the market in 2019. This growth is attributed to various factors such as a rise in the consumption of CBD-based products in weight management, health and wellness, sports nutrition, and other fields. In addition, companies are constantly trying to diversify their products into different forms to cater to a larger consumer pool to improve product penetration into newer consumer segments and to increase brand visibility. Companies are undertaking various strategic initiatives to expand their presence in the market. For instance, in March 2020, Reakiro, a European CBD company, launched its CBD products-including capsules, oils, and soft gels-in the U.S., after looking at the significant demand for CBD-infused dietary supplements and products in the country. On the other hand, CBDa products are anticipated to witness the fastest growth over the forecast period owing to potential health benefits offered by these products as well as increasing efficiency in managing health conditions.

Moreover, the health benefits of cannabinoids and affirmative research efforts that can demonstrate the benefits of these products in conditions such as analgesia, sleep disorders, and mental disorders have fueled the market in the country. For instance, a study of 72 adults suffering from anxiety and sleep disorders in the U.S. was carried out by The Permanente Journal in 2019. After one month of undergoing treatment with 25 mg CBD capsules, around 66.0% of patients indicated lesser trouble with sleeping. The rise in the number of manufacturers offering bulk as well and finished cannabinoid products is boosting market growth in the country. The ongoing COVID-19 pandemic is further impacting the overall cannabis industry in the region. As per Orange County Register, on March 17, 2020, some dispensaries such as Bud and Bloom witnessed an overall increase in weekly sales by over 30.0%.

U.S. Cannabinoids Market Report Highlights

• The size is anticipated to be valued at USD 16.4 billion by 2027, owing to increasing legalization of these products

• CBD products dominated the market in 2019, owing to affirmative legal scenarios, ease of accessibility, and increase in awareness about CBD

• CBDa products are anticipated to witness the fastest growth over the forecast period owing to potential health benefits and higher efficiency in managing health conditions"

 "Table of Contents

Chapter 1 Methodology and Scope
                 1.1 Research Methodology
                     1.1.1 Information Procurement
                 1.2 Information or Data Analysis
                 1.3 Market Formulation & Validation
                     1.3.1 CAGR Calculation
                 1.4 Region Based Segment Share Calculation
                 1.5 List of Secondary Sources
Chapter 2 Executive Summary
                 2.1 Market Summary
Chapter 3 U.S. Cannabinoids Market Variables, Trends & Scope
                 3.1 Market Segmentation
                 3.2 Penetration & Growth Prospects Mapping
                 3.3 U.S. Cannabinoids Market Dynamics
                     3.3.1 Market Driver Analysis
                         3.3.1.1 Growing number of new entrants in the market leading to expansion in product availability
                         3.3.1.2 Increasing number of consumers opting for isolated cannabinoid products
                         3.3.1.3 Growing number of clinical studies on the use of cannabinoids for specific applications
                         3.3.1.4 Rising awareness pertaining to cannabinoid products and their use in health and wellness
                     3.3.2 Market Restraint Analysis
                         3.3.2.1 High price of cannabinoids-based products
                         3.3.2.2 Expensive extraction processes for cannabinoids
                         3.3.2.3 Absence of definite regulatory framework for minor cannabinoids
                 3.4 U.S. Cannabinoids Market Analysis Tools
                     3.4.1 U.S. Cannabinoids Market - PESTLE Analysis
                     3.4.2 U.S. Cannabinoids Market - Porter’s Analysis
                 3.5 Supply Chain Analysis
                     3.5.1 Supply Chain Analysis - CBD Consumer Health Product
                         3.5.1.1 Profit Margin Estimation
                 3.6 Opportunity Analysis
                 3.7 Regulatory Scenario
                 3.8 Product Adoption Pattern Analysis
                     3.8.1 Cannabidiol (CBD)
                     3.8.2 Tetrahydrocannabinol (THC)
                     3.8.3 Cannabinol (CBN)
                     3.8.4 Cannabidiolic Acid (CBDA)
                     3.8.5 Others
                         3.8.5.1 Cannabigerol (CBG)
                         3.8.5.2 Cannabichromene (CBC)
                 3.9 Pricing Analysis, Product Type, 2019-2027
Chapter 4 U.S Cannabinoids Market: Product Estimates & Trend Analysis
                 4.1 U.S. Cannabinoids Market: Product Movement Analysis
                 4.2 Market Revenue Size and Forecasts and Trend Analysis 2016-2027 for the following product types:
                     4.2.1 Cannabidiol (CBD)
                         4.2.1.1 CBD Market Estimates and Forecasts, 2016 - 2027 (USD Million)
                     4.2.2 Tetrahydrocannabinol (THC)
                         4.2.2.1 THC Market Estimates and Forecasts, 2016 - 2027 (USD Million)
                     4.2.3 Cannabinol (CBN)
                         4.2.3.1 CBN Market Estimates and Forecasts, 2016 - 2027 (USD Million)
                     4.2.4 Cannabidiolic Acid (CBDA)
                         4.2.4.1 CBDa Market Estimates and Forecasts, 2016 - 2027 (USD Million)
                     4.2.5 Other Cannabinoids (CBG AND CBC)
                         4.2.5.1 Other Cannabinoids (CBG and CBC) Market Estimates and Forecasts, 2016 - 2027 (USD Million)
Chapter 5 Competitive Landscape
                 5.1 Company Profiles
                     5.1.1 Mile High Labs International
                         5.1.1.1 Company overview
                         5.1.1.2 Financial performance
                         5.1.1.3 Product benchmarking
                         5.1.1.4 Strategic initiatives
                     5.1.2 Global Cannabinoids
                         5.1.2.1 Company overview
                         5.1.2.2 Financial performance
                         5.1.2.3 Product benchmarking
                         5.1.2.4 Strategic initiatives
                     5.1.3 Gencanna
                         5.1.3.1 Company overview
                         5.1.3.2 Financial performance
                         5.1.3.3 Product benchmarking
                         5.1.3.4 Strategic initiatives
                     5.1.4 CBD Inc Group
                         5.1.4.1 Company overview
                         5.1.4.2 Product benchmarking
                     5.1.5 SPARKCBD
                         5.1.5.1 Company overview
                         5.1.5.2 Product benchmarking
                     5.1.6 Rhizo Sciences
                         5.1.6.1 Company overview
                         5.1.6.2 Financial performance
                         5.1.6.3 Product benchmarking
                         5.1.6.4 Strategic initiatives
                     5.1.7 Maricann, Inc.
                         5.1.7.1 Company overview
                         5.1.7.2 Product benchmarking
"

"List of Tables

Table 1 Partial list of secondary sources
Table 2 Average Selling price of cannabinoids in the U.S., by product, 2019 - 2027 (USD/mg)"	"List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. Cannabinoids market snapshot, 2019 (USD Million)
Fig. 9 U.S. Cannabinoids market dynamics
Fig. 10 U.S.Cannabinoids market segmentation
Fig. 11 Penetration & growth prospects mapping for U.S. Cannabinoids market
Fig. 12 U.S. Cannabinoids market driver impact
Fig. 13 U.S. Cannabinoids market restraints impact
Fig. 14 U.S. Cannabinoids market - PESTLE analysis
Fig. 15 U.S. Cannabinoids market - Porter’s Analysis
Fig. 16 Supply chain network of CBD isolates and full spectrum extracts
Fig. 17 Supply chain network of CBD isolates and full spectrum distillates
Fig. 18 Methods of estimation
Fig. 19 Opportunity analysis (USD Million)
Fig. 20 U.S. Cannabinoids market, Product outlook: Key takeaways
Fig. 21 U.S. Cannabinoids market: Product movement analysis (2019 & 2027) (USD Million)
Fig. 22 CBD market estimates and forecasts, 2016 - 2027 (USD Million)
Fig. 23 THC market estimates and forecasts, 2016 - 2027 (USD Million)
Fig. 24 CBN market estimates and forecasts, 2016 - 2027 (USD Million)
Fig. 25 CBDa market estimates and forecasts, 2016 - 2027 (USD Million)
Fig. 26 Other cannabinoids market estimates and forecasts, 2016 - 2027 (USD Million)"